Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00523250 · ClinicalTrials.gov registry record · Phase 2
Ocular Hypotensive Efficacy of AR-102
A Phase 2 study, sponsored by Aerie Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 82
- Enrollment target
NCT00523250: Completed Phase 2 study, sponsored by Aerie Pharmaceuticals.
NCT00523250 is a Phase 2 study that has completed, run by Aerie Pharmaceuticals. The registered enrollment target is 82 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (38% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00523250, a Phase 2 study, has completed, sponsored by Aerie Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 82 participants
- Enrollment target
Study Summary
A double-masked, randomized, vehicle-controlled, dose-response study assessing the safety and ocular hypotensive efficacy of AR-102 in subjects with elevated intraocular pressure. The Null hypothesis is that the ocular hypotensive efficacy of each dose of AR-102 Ophthalmic Solution will not be different from that of its vehicle.
Interventions
- DRUG AR-102 0.003% Ophthalmic Solution
- DRUG AR-102 0.005% Ophthalmic Solution
- DRUG AR-102 0.01% Ophthalmic Solution
- DRUG AR-102 0.03% Ophthalmic Solution
- DRUG AR-102 Vehicle Ophthalmic Solution
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 82 participants |
| Start Date | 2007-09 |
| Est. Completion | 2008-03 |
| Phase | Phase 2 |
What the finished NCT00523250 record still lists
NCT00523250 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 82 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (38% lower).
The record links to 0 conditions, and to 5 interventions - of which AR-102 0.003% Ophthalmic Solution is the first listed.
NCT00523250 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00523250 about?
NCT00523250 is a clinical study titled "Ocular Hypotensive Efficacy of AR-102". A double-masked, randomized, vehicle-controlled, dose-response study assessing the safety and ocular hypotensive efficacy of AR-102 in subjects with elevated intraocular pressure. The Null hypothesis is that the ocular hypotensive efficacy of each dose of AR-102 Ophthalmic Solution will not be diffe...
What is the current status of trial NCT00523250?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 82 participants. The study started on 2007-09. Estimated completion is 2008-03.
What interventions are being tested in trial NCT00523250?
The interventions under investigation include: AR-102 0.003% Ophthalmic Solution (DRUG), AR-102 0.005% Ophthalmic Solution (DRUG), AR-102 0.01% Ophthalmic Solution (DRUG), AR-102 0.03% Ophthalmic Solution (DRUG), AR-102 Vehicle Ophthalmic Solution (DRUG).
Who is sponsoring clinical trial NCT00523250?
This trial is sponsored by Aerie Pharmaceuticals, which has 32 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00523250's enrollment target sits among peer trials
82 830th of 2000 higher than 1,167 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03319901 · 82 participants · Phase 1
Venetoclax and Chemotherapy as Frontline Therapy in Older Patients and Patients With Relapsed/Refractory ALL
- NCT03493425 · 82 participants · Phase 2
Chemotherapy Before Surgery and Radiation Therapy or Surgery and Radiation Therapy Alone in Treating Patients With Nasal and Paranasal Sinus Cancer That Can Be Removed by Surgery
- NCT04105270 · 82 participants · Phase 2
RMT in Combination With Durvalumab + Chemo in Untreated Adenocarcinoma NSCLC. A Randomized Double Blind Phase II Trial
- NCT04428658 · 82 participants · NA
Randomized Trial of Supplemental Synchronous and Asynchronous Telehealth to Improve Glycemic Control for Pediatric Patients With Type 1 Diabetes
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia